# A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma

> **NCT01308684** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 22 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** RO5323441 + bevacizumab [Avastin]
- **DRUG:** bevacizumab [Avastin]

## Key facts

- **NCT ID:** NCT01308684
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01308684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01308684, "A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01308684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*